Cargando…
Clinicopathological and Prognostic Value of Programmed Cell Death 1 Expression in Hepatitis B Virus-related Hepatocellular Carcinoma: A Meta-analysis
BACKGROUND AND AIMS: The efficacy of targeted programmed cell death 1/programmed death ligand 1 (PD-1/PD-L1) monoclonal antibodies (mAbs) has been confirmed in many solid malignant tumors. The overexpression of PD-1/PD-L1 serves as a biomarker to predict prognosis and clinical progression. However,...
Autores principales: | Zhou, Zi-Yu, Liu, Shao-Ru, Xu, Lei-Bo, Liu, Chao, Zhang, Rui |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
XIA & HE Publishing Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8666368/ https://www.ncbi.nlm.nih.gov/pubmed/34966652 http://dx.doi.org/10.14218/JCTH.2021.00056 |
Ejemplares similares
-
Prognostic and Clinicopathological Value of Programmed Death Ligand-1 in Breast Cancer: A Meta-Analysis
por: Guo, Yawen, et al.
Publicado: (2016) -
Clinicopathologic Significance and Prognostic Value of Programmed Cell Death Ligand 1 (PD-L1) in Patients With Hepatocellular Carcinoma: A Meta-Analysis
por: Li, Jing-Hua, et al.
Publicado: (2018) -
The clinicopathological significance and prognostic value of programmed death-ligand 1 in prostate cancer: a meta-analysis of 3133 patients
por: Shen, Haixiang, et al.
Publicado: (2020) -
Prognostic and clinicopathological value of MUC1 expression in colorectal cancer: A meta-analysis
por: Li, Chao, et al.
Publicado: (2019) -
Prognostic and clinicopathological value of Beclin-1 expression in hepatocellular carcinoma: a meta-analysis
por: Qin, Zhiqiang, et al.
Publicado: (2018)